✦ LIBER ✦

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

✍ Scribed by Seto, Takashi; Kato, Terufumi; Nishio, Makoto; Goto, Koichi; Atagi, Shinji; Hosomi, Yukio; Yamamoto, Noboru; Hida, Toyoaki; Maemondo, Makoto; Nakagawa, Kazuhiko; Nagase, Seisuke; Okamoto, Isamu; Yamanaka, Takeharu; Tajima, Kosei; Harada, Ryosuke; Fukuoka, Masahiro; Yamamoto, Nobuyuki

Book ID: 126668784
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 398 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70381-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erlotinib versus chemotherapy as first-l

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

✍ Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 265 KB

Erlotinib versus standard chemotherapy a

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

✍ Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massut 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB

Afatinib versus cisplatin plus gemcitabi

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

✍ Wu, Yi-Long; Zhou, Caicun; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yuncha 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 388 KB

A prospective, phase II, open-label stud

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

✍ Goto, Koichi; Nishio, Makoto; Yamamoto, Noboru; Chikamori, Kenichi; Hida, Toyoak 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 948 KB

6594 POSTER First-line bevacizumab in co

6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390)

✍ Crinó, L.; Dansin, E.; Garrido Lopez, P.; Griesinger, F.; Laskin, J.; Pavlakis, 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Efficacy and safety of erlotinib versus

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

✍ Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 381 KB